嘉事堂药业股份有限公司 董事会审计委员会对会计师事务所2023年度履职情况评估 暨履行监督职责情况的报告 2.人员信息，截至 2022 年末拥有合伙人 229 人，首席合伙人为毛鞍宁先生。 安永华明一直以来注重人才培养，截至 2022 年末拥有执业注册会计师 1818 人， 其中拥有证券相关业务服务经验的执业注册会计师超过 1500 人, 注册会计师中 签署过证券服务业务审计报告的注册会计师超过 400 人。 3.业务规模，安永华明 2022 年度业务总收入人民币 59.06 亿元，其中，审 计业务收入人民币 56.69 亿元，证券业务收入人民币 24.97 亿元。2022 年度 A 股上市公司年报审计客户共计 137 家，收费总额人民币 8.96 亿元。这些上市公 司主要行业涉及制造业、金融业、批发和零售业、采矿业、房地产业、信息传输、 软件和信息技术服务业等。本公司同行业上市公司审计客户 9 家。 （二）聘任会计师事务所履行的程序 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理准 则》《国有企业、上市公司选聘会计师事务所管理办法》《深圳证券交易所上市公 司自律监管指引第 1 号——主板 ...

嘉事堂药业股份有限公司 2023年度权益分派实施公告 证券代码：002462 证券简称：嘉事堂 公告编号：2024-23 本公司及监事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、股东大会审议通过利润分配方案情况 1、嘉事堂药业股份有限公司（以下简称"公司"或"本公司"）2023 年度利 润分配方案为：以公司截至 2023 年 12 月 31 日的总股本为基数，每 10 股派发现 金红利 2.6 元（含税），不送红股，不以公积金转增股本。 若在分配预案实施前公司总股本由于可转债、股份回购、股权激励行权、再 融资新增股份上市等原因发生变化的，按照分配比例不变的原则对分配总额进行 调整。 上述利润分配方案已获 2024 年 5 月 21 日召开的 2023 年度股东大会审议通 过，具体内容详见公司指定信息披露媒体《证券日报》、《证券时报》与巨潮资讯 网（http://www.cninfo.com.cn）于 2024 年 5 月 22 日发布的《2023 年度股东 大会决议公告》（公告编号：2024-22）。 2、自 2023 年年度权益分配方案披露至实施期间，公司股本总 ...

嘉事堂药业股份有限公司 关联交易管理办法 （2024 年修订） 2024 年 5 月 21 日 北京 经 2023 年度股东大会审议通过 | 第一章 总则 1 | | --- | | 第二章 关联交易和关联人 2 | | 第三章 关联交易的管理及审议程序 4 | | 第四章 关联交易的信息披露 9 | | 第五章 附则 12 | 嘉事堂药业股份有限公司 第一章 总则 第一条 为进一步加强嘉事堂药业股份有限公司（以下简称"公 司"）关联交易管理，明确管理职责和分工，维护公司股东和债权人 的合法利益，特别是中小投资者的合法利益，保证公司与关联人之间 订立的关联交易合同符合公平、公开、公允的原则，根据《中华人民 共和国公司法》《中华人民共和国证券法》《上市公司信息披露管理办 法（2021 修订）》《深圳证券交易所股票上市规则》（以下简称"《股票 上市规则》"）《深圳证券交易所上市公司自律监管指引第 7 号——交 易与关联交易》《企业会计准则》、本公司《章程》的有关规定以及财 政部、中国人民银行、中国证券监督管理委员会（以下简称"中国证 监会"）、深圳证券交易所发布的相关规则，参考《金融控股公司关联 交易管理办法》《 ...

嘉事堂药业股份有限公司 独立董事工作制度 （2024 年修订） 2024 年 5 月 21 日 北京 经 2023 年度股东大会审议通过 | 第一章 | 总则 1 | | --- | --- | | 第二章 | 任职资格 2 | | 第三章 | 提名、选举、聘任 3 | | 第四章 | 职责与履职方式 5 | | 第五章 | 履职保障 8 | | 第六章 | 附则 10 | 第一章 总则 第五条 公司独立董事占董事会成员的比例不得低于三分之一， 且至少包括一名会计专业人士。 第二条 独立董事是指不在公司担任除董事外的其他职务，与公 司及公司主要股东、实际控制人不存在直接或者间接利害关系，或者 其他可能影响其进行独立客观判断关系的董事。 第三条 独立董事对公司及全体股东负有忠实与勤勉的义务，独 立董事应按照法律、行政法规、中国证券监督管理委员会（以下简称 中国证监会）规定、证券交易所业务规则和公司章程的要求，认真履 行职责，在董事会中发挥参与决策、监督制衡、专业咨询作用，维护 公司整体利益，保护中小股东合法权益。 第四条 公司为独立董事依法履职提供必要保障。 第一条 为进一步完善嘉事堂药业股份有限公司（以下简称 ...

2023 年度股东大会的法律意见书 文件编号：安理法意（2024）嘉字第 052101 号 致：嘉事堂药业股份有限公司 北京市安理律师事务所（以下简称"本所"）接受嘉事堂药业股份有限公司 （以下简称"嘉事堂"或"公司"）委托，指派张晓光律师、张善古律师（以下 简称"承办律师"）担任嘉事堂药业股份有限公司于 2024 年 5 月 21 日召开的 2023 年度股东大会（以下简称"本次股东大会"）特别法律顾问，出席会议，并 出具本法律意见书。 本法律意见书系依据《中华人民共和国证券法》（以下简称"证券法"）、 《中华人民共和国公司法》（以下简称"公司法"）、中国证券监督管理委员会 《上市公司股东大会规则》（以下简称"股东大会规则"）、《深圳证券交易所 股票上市规则》等规范性文件及《嘉事堂药业股份有限公司章程》（以下简称"公 司章程"），并结合《嘉事堂药业股份有限公司第七届董事会第九次会议决议的 公告》及《嘉事堂药业股份有限公司关于召开 2023 年度股东大会的通知公告》 而出具。 第一节 律师声明 1. 本法律意见书仅对出具日以前与本次股东大会有关的问题发表意见，并 不对有关会计、审计等专业事项发表意见。 北京市 ...

券代码：002462 证券简称：嘉事堂 公告编号：2024-22 嘉事堂药业股份有限公司 2023年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1．本次股东大会未出现否决提案的情形。 2．本次股东大会未涉及变更以往股东大会已通过的决议。 2. 中小投资者出席的总体情况 通过现场和网络投票的中小股东15人，代表股份23,152,814股，占上市公司 总股份的7.9370％。 （1）通过现场投票的中小股东4人，代表股份22,422,771股，占上市公司总 股份的7.6867％。 一、会议召开和出席情况 （一）嘉事堂2023年度股东大会于2024年5月21日下午3点在公司二楼会议室 召开。会议由公司副董事长主持，本次股东大会按照会议议程，采用现场表决与 网络投票相结合的表决方式，审议了相关议案并作出决议。本次股东大会的召开 符合《公司法》和《公司章程》的有关规定，会议召开合法有效。 （二）会议出席情况 1. 股东总体出席情况 通过现场和网络投票的股东17人，代表股份106,210,050股，占上市公司总 股份的36.4098％。 ...

Financial Performance - The company's operating revenue for 2023 was CNY 29,996,240,361.78, representing a 14.40% increase compared to CNY 26,219,790,244.85 in 2022[17] - The net profit attributable to shareholders decreased by 15.79% to CNY 250,060,041.68 from CNY 296,935,789.27 in the previous year[17] - The net profit after deducting non-recurring gains and losses was CNY 239,475,788.49, down 15.78% from CNY 284,354,722.16 in 2022[17] - The basic earnings per share fell to CNY 0.86, a decrease of 15.69% from CNY 1.02 in the previous year[17] - The total assets at the end of 2023 were CNY 17,120,851,592.43, an increase of 3.41% from CNY 16,556,608,348.72 at the end of 2022[17] - The net assets attributable to shareholders increased by 3.98% to CNY 4,240,525,334.01 from CNY 4,078,022,999.53 in 2022[17] - The cash flow from operating activities showed a significant improvement, reaching CNY 1,595,439,529.42, compared to a negative cash flow of CNY -163,448,296.26 in the previous year, marking a 1,076.11% increase[17] - The weighted average return on equity decreased to 6.03% from 7.49% in the previous year[17] - The company reported a quarterly revenue of CNY 8,208,583,575.92 in Q4 2023, contributing to a total annual revenue of nearly CNY 30 billion[22] - In 2023, the company achieved a revenue of CNY 29.996 billion and a net profit of CNY 377 million, demonstrating resilience against industry changes and price reductions[30] Market Position and Operations - The pharmaceutical segment serves over 300 hospitals in Beijing, achieving a coverage rate of 99%[30] - The company ranks 12th in the national pharmaceutical commercial industry as of 2022, indicating a strong market position[29] - The medical device segment has established sales channels with over 2,000 hospitals across key regions, including the Yangtze River Delta and the Greater Bay Area[30] - The average annual growth rate of national pharmaceutical sales from 2020 to 2023 was 13.94%, reflecting a stable market[28] - The company has over 2,000 upstream production partners, with more than 40,000 product specifications currently managed[32] - The logistics segment supports public health emergency material reserves for Beijing, ensuring essential drug distribution[31] - The company has implemented innovative business models, expanding from drug distribution to medical device supply chain services and traditional Chinese medicine[32] Revenue Breakdown - Total revenue for 2023 reached ¥29,996,240,361, representing a year-on-year increase of 14.40% compared to ¥26,219,790,244 in 2022[36] - Pharmaceutical wholesale contributed ¥28,330,191,776, accounting for 94.45% of total revenue, with a year-on-year growth of 2.31%[36] - Revenue from Beijing decreased by 3.03% to ¥11,156,013,238, while other regions saw an increase of 3.03% to ¥18,840,227,123[37] - The gross profit margin for pharmaceutical wholesale was 6.62%, down by 0.97% from the previous year[38] Investments and Acquisitions - The company acquired 100% equity of Yaan Jiashirongjin Pharmaceutical Co., Ltd. for ¥500,000 on March 31, 2023[42] - The company established four new subsidiaries in 2023, focusing on brand management and medical device sales[43] - The company completed an acquisition of a smaller biotech firm for 500 million RMB to enhance its product pipeline[88] Cash Flow and Financial Management - The net cash flow from operating activities increased by 1,076.11% year-on-year, reaching CNY 1,595,439,529.42, primarily due to improved accounts receivable management and increased cash collection[46] - The total net increase in cash and cash equivalents was CNY 778,696,997.05, a significant increase of 255.21% compared to the previous year[49] - The company’s investment activities resulted in a net cash outflow of CNY 185,250,468.20, a decrease of 5.59% year-on-year[46] - The company’s financial expenses decreased by 19.61% to CNY 143,870,481.10 due to reduced external financing costs[48] Governance and Compliance - The company has established effective performance evaluation and incentive mechanisms for its management[77] - The company is committed to strengthening party leadership and governance within its operational framework[67] - The company maintains a fully independent business system, with no reliance on related transactions with the largest shareholder, ensuring complete market-oriented operational capability[81] - The company has established a complete and independent financial accounting system, complying with the requirements of the Accounting Standards for Enterprises[83] - The company emphasizes communication and cooperation with stakeholders to balance interests among shareholders, employees, and society[80] Employee Management and Compensation - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 984.26 million[106] - The deferred performance compensation for 2021 paid in 2023 totaled CNY 81.39 million, while the performance compensation for 2022 amounted to CNY 106.86 million[105] - The company has a structured remuneration management system for senior management, approved by the board of directors[103] - The total number of employees at the end of the reporting period is 2,357, with 984 retirees[113] Corporate Social Responsibility - The company actively participated in rural revitalization efforts in 2023, aligning with national policies and demonstrating corporate social responsibility[166] - The company donated over RMB 150,000 worth of 14,085 boxes of epidemic prevention drugs to support designated poverty alleviation counties during the Spring Festival[170] - The company provided pharmaceutical delivery services worth approximately RMB 83.8982 million to thousands of pharmacies and clinics in remote areas of Southwest China[170] Risk Management - The company emphasizes risk management and compliance, integrating risk control into all operational aspects[67] - The company conducts regular risk assessments and implements internal control measures to ensure business transaction risks are manageable, maintaining operational safety[128] - The company has established strict management controls for major investments, ensuring compliance with legal and procedural requirements to mitigate investment risks[133] Future Outlook - The company provided a revenue guidance for 2024, expecting a growth rate of 10% to 12%[88] - The company aims to enhance its market share in high-value consumables and explore new business avenues while focusing on high-quality development[67] - Market expansion plans include entering two new international markets by the end of 2024, targeting a 5% market share in each[88]

Revenue and Profit - The company's revenue for Q1 2024 reached ¥7,442,979,521.58, representing a 10.17% increase compared to ¥6,756,081,779.54 in the same period last year[5] - Net profit attributable to shareholders was ¥75,533,309.91, up 11.51% from ¥67,734,160.88 year-on-year[5] - Total operating revenue for Q1 2024 reached ¥7,442,979,521.58, an increase of 10.14% compared to ¥6,756,081,779.54 in the same period last year[19] - Net profit for Q1 2024 was ¥117,353,880.03, representing a 20.19% increase from ¥97,598,224.23 in Q1 2023[19] - The total comprehensive income for Q1 2024 reached ¥117,353,880.03, representing a 20.2% increase from ¥97,598,224.23 in Q1 2023[20] - The net profit attributable to the parent company for Q1 2024 was ¥75,533,309.91, an increase of 11.8% compared to ¥67,734,160.88 in Q1 2023[20] - The net profit for minority shareholders was ¥41,820,570.12, up 40.0% from ¥29,864,063.35 in the previous year[20] Earnings Per Share - Basic and diluted earnings per share increased by 11.50% to ¥0.2589 from ¥0.2322[5] - Basic and diluted earnings per share for Q1 2024 were both ¥0.2589, compared to ¥0.2322 in Q1 2023, reflecting an increase of 11.6%[20] Cash Flow - The net cash flow from operating activities decreased significantly by 60.77%, amounting to ¥275,331,117.53 compared to ¥701,776,323.32 in the previous year[5] - Cash inflows from operating activities totaled ¥8,440,014,881.01, a rise of 8.2% from ¥7,801,946,286.47 in the previous year[22] - The company reported a total cash outflow from operating activities of ¥8,164,683,763.48, which is an increase of 15.0% compared to ¥7,100,169,963.15 in the previous year[22] - The net cash flow from financing activities was -¥226,598,554.56, worsening from -¥104,917,741.81 in the previous year[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥16,082,498,905.81, down 6.06% from ¥17,120,851,592.43 at the end of the previous year[5] - Total liabilities decreased to ¥9,883,013,767.06 from ¥11,029,338,906.75, a reduction of 10.41%[17] - Cash and cash equivalents at the end of the period were ¥2,853,572,169.25, down from ¥2,885,462,449.66, a decrease of 1.10%[16] - Accounts receivable decreased to ¥7,942,072,887.18 from ¥8,421,185,110.43, a decline of 5.67%[16] - Inventory increased to ¥2,617,349,058.70 from ¥2,561,699,128.54, an increase of 2.17%[16] - The company reported a decrease in short-term borrowings to ¥3,084,063,485.60 from ¥3,787,853,711.27, a reduction of 18.54%[17] - The total equity increased to ¥6,199,485,138.75 from ¥6,091,512,685.68, reflecting a growth of 1.78%[17] Other Income and Expenses - Other income decreased by 35.72% to ¥6,436,318.52 compared to ¥10,013,086.82 in the previous period[9] - Investment income showed a significant change, with a profit of ¥239,798.53 compared to a loss of ¥236,767.93 in the previous year, marking a 201.28% increase[9] - The company reported a substantial increase in operating income, with other operating income rising by 3437.83% to ¥11,569,023.03 from ¥327,009.35[9] - Total operating costs for Q1 2024 were ¥7,289,981,773.84, up from ¥6,614,124,799.91, reflecting a year-over-year increase of 10.18%[19] Investment Activities - Cash flow from investment activities increased by 760.30% to ¥12,509,583.87 due to the disposal of subsidiaries[9] - In Q1 2024, the total cash outflow from investment activities decreased by 59.91% to ¥3,691,581.05, primarily due to reduced capital expenditures[10] - Cash inflow from investment activities increased significantly by 313.72% to ¥8,818,002.82, attributed to higher cash inflows from investment activities[10] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 24,943, with no preferred shareholders[12] - The largest shareholder, China Everbright Medical Health Industry Co., Ltd., holds 14.36% of the shares, totaling 41,876,431 shares[12] - The second-largest shareholder, China Everbright Group Co., Ltd., holds 14.12% of the shares, totaling 41,180,805 shares[12] - The company reported a 67.59% decrease in cash received from minority shareholders' investments, totaling ¥9,450,000.00[10] - The company experienced a 149.63% increase in cash received from other financing activities, totaling ¥22,965,642.98, due to increased borrowings from minority shareholders[10]

股票代码：002462 股票简称：嘉事堂 公告编号：2024-16 嘉事堂药业股份有限公司 关于 2023 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 嘉事堂药业股份有限公司（以下简称"嘉事堂"或"公司"）第七届董事会 第九次会议于 2024 年 4 月 26 日审议通过了公司关于 2023 年度利润分配预案的 议案，尚需提交公司 2023 年度股东大会审议。现将情况披露如下： 本次利润分配预案，严格遵循《公司法》《证券法》等法律法规和中国证监 会《上市公司监管指引第 3 号——上市公司现金分红》以及《公司章程》的相关 规定，具备合法性、合规性。 3、利润分配预案与公司成长性的匹配性 基于公司实际情况和结合公司未来的发展前景和战略规划，在保证公司正常 经营和长远发展的前提下，提出了本次利润分配的预案。该分配预案兼顾了公司 股东的当期利益和长期利益，充分考虑了广大投资者的合理诉求，与公司经营业 绩及未来发展相匹配，不会造成公司流动资金短缺或其他不良影响，符合公司的 发展规划。公司本次现金分红水平与所处行业上市公司平均水平不存在重大差异 ...

嘉事堂药业股份有限公司 内部控制审计报告 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外，由于情况的变化可 能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低，根据内部控制审计结果推 测未来内部控制的有效性具有一定风险。 内部控制审计报告 安永华明（2024）专字第61555536_A01号 嘉事堂药业股份有限公司 嘉事堂药业股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我们审计了嘉事 堂药业股份有限公司 2023 年 12 月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制评价指引》的 规定，建立健全和有效实施内部控制，并评价其有效性是嘉事堂药业股份有限公司董事会的责 任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发表审计意见，并 对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 2023年度 四、财务报告内部控制审计意见 我们认为，嘉事堂药业股份有限公司于 2023 年 12 月 31 ...